Hodgkin's lymphoma (HL) patients with positive 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) post salvage chemotherapy or before high-dose chemotherapy and auto-SCT (HDC ASCT) have inferior outcomes. We reviewed 21 prognostic factors before salvage chemotherapy (at relapse/progression) and integrated post salvage FDG-PET results to develop a prognostic model for post HDC ASCT outcome. We used Fine and Gray method for competing risk analysis and regression model for risks assessment and outcome. One hundred and forty-one patients had post salvage FDG-PET before HDC ASCT (median age 25.5 years); male/female 55%:45%, relapsed/refractory 43%:57%, median follow-up 33 months. Multivariate analysis identified HL International Prognostic Score X3 (P ¼ 0.001; hazard ratio (HR): 3.7 (1.6-8.3)) and post salvage positive FDG-PET (P ¼ 0.011; HR: 3.4 (1.3-8.9)) with higher hazard of disease-specific death (model P ¼ 0.0001). Cumulative incidence of disease-specific death with 0, 1, 2 risk factors was 7%:29%:52%, respectively (P ¼ 0.00003). For disease-specific event (persistent, progressive or relapsed disease), mediastinal involvement (P ¼ 0.024; HR: 2.7 (1.14-6.5)), B symptoms (P ¼ 0.027; HR: 2.1 (1.09-4.2)) and positive post salvage FDG-PET (P ¼ 0.001; HR: 3.3 (1.7-6.7)) were significant (model P ¼o0.00001). Cumulative incidence of disease-specific event with 0, 1, 2, 3 risk factors was 8%:31%:50%:75%, respectively (P ¼ 0.0000006). Patients with higher scores have higher risk of treatment failure. They are potential candidates for newer therapies along with HDC ASCT.
INTRODUCTION
Patients with refractory or relapsed Hodgkin's lymphoma (HL) can still be salvaged with high-dose chemotherapy and auto-SCT (HDC ASCT). HDC ASCT has shown superior EFS and OS in these patients when compared with salvage chemotherapy alone. [1] [2] [3] [4] There has been increasing use of 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) scanning for response assessment after salvage chemotherapy or before HDC ASCT in patients with HL. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Patients with FDG-PET-positive disease after salvage chemotherapy or before HDC ASCT have been reported to have inferior outcome. Currently, there is no comprehensive predictive model integrating FDG-PET with other pre-salvage clinical risk factors in this group. We are reporting our experience of post salvage chemotherapy or pre-transplant FDG-PET results along with other prognostic factors and constructed a predictive model and its impact on post HDC ASCT outcome.
MATERIALS AND METHODS
This is a combined report of Institutional Research Advisory Council-approved prospective trial and prospective data collection study. All patients and/or their guardians provided informed consent for all treatments, procedures and HDC ASCT as per institutional requirements. Details of methodology and design are fully explained in our previous report. 17 This study evaluates the impact of post salvage chemotherapy or pre-HDC ASCT FDG-PET among other prognostic or predictive factors at the time of relapse or progression before the initiation of salvage chemotherapy on post HDC ASCT persistent disease, progression, relapse or death in patients who underwent HDC ASCT. We also constructed a score-based predictive model based on pre-transplant FDG-PET results and other prognostic factors for post HDC ASCT residual/progressive disease (PD), relapse and death due to disease in these patients.
Patients
All patients with relapsed or primary refractory HL who underwent HDC ASCT in the Section of Adult Medical Oncology were identified from Oncology Research Unit. Paper and electronic charts were reviewed to collect required data. Data were collected for prospective lymphoma data base, SCT database and FDG-PET trial at various time frames. Before HDC ASCT, all patients were required to have adequate hematological, renal, hepatic, pulmonary and cardiac functions and treatment was approved in stem cell meeting. In our institution, these patients were managed/supervised by the lymphoma and HDC ASCT service physicians (SA and IM).
Definitions
All patients were staged according to Ann Arbor Cotswolds modification staging system. Bulky disease was defined as mediastinal mass greater than or equal to one-third of the maximum thoracic wall diameter or any mass X8 cm (8 cm is our institution's cutoff for bulky disease for HL). International Working Group 18 response criteria were used for computed tomography (CT) scan: CR, disappearance of all lymphoma-related abnormalities; PR, more than 50% reduction; no response or stable disease as less than PR; PD as appearance of any new lesion or more than 25% increase in the presence of previous lesion or appearance of disease-related symptoms. There is no consensus as how to define refractory disease in HL. Many different definitions are used as we had discussed in our previous paper and used the same definition like before; 19 refractory disease was defined as PR, no response or stable disease or PD after planned multiagent chemotherapy with or without radiation therapy (XRT) or relapsing within 3 months of finishing the planned treatment after achieving a CR or CR unconfirmed. Older studies used only CT scans for disease status and we are using FDG-PET-based definition, which is considered more accurate. For CT scan and FDG-PET, 'positive study' was defined as study showing evidence of disease (PR, no response or stable disease, PD) and 'negative study' as study showing no evidence of disease (CR, CR unconfirmed, continuous CR) as described in FDG-PET and CT reading sections. Details of prognostic factors are provided in statistical section and Table 1 . HL International Prognostic Score (HL-IPS) was also calculated at the time of initial presentation and before starting salvage chemotherapy as the number of poor risk features present based on male gender, age X45 years, albumin o4 g/dL, hemoglobin o10.5 g/dL, stage IV, white blood cell X15 000/mm 3 , lymphocyte o600/mm 3 and/or o8% of total white blood cell. 20 HL-IPS before salvage chemotherapy is used in all analysis.
FDG-PET imaging and reading
FDG-PET data of the whole body were obtained on PET-CT Discovery LS system (8 slice CT) by GE (Milwaukee, WI, USA) (four patients before October 2005 were scanned on ECAT EXACT scanner, Siemens-CTI, Knoxville, TN, USA). Patients received a dose of 370-444 MBq FDG intravenously and scanned from mid-thigh to the crown upwards starting 90 min after injection. The measured axial field of view extended over 45FDG cm (3 bed positions). Forty-seven overlapping slices per bed position were acquired. Corrections for attenuation were based on measured transmission scans. Positive FDG-PET was defined as any focal or diffuse area of increased activity in a location incompatible with normal anatomy/physiology and suspect for residual disease on visual assessment. Mediastinal blood pool structure activity was used as a reference for normal uptake for residual masses 42 cm. 'Positive' results were semi-quantitatively investigated using the standardized uptake value. All FDG-PETs were reviewed by two experienced nuclear medicine experts (AAl-S and M Abouzied) as per uniformed guidelines. CT scans were reported as per institutional guidelines and scans were re-reviewed when needed by one body CT expert (YAl-K). Radiologist or nuclear medicine physicians were not aware of the patient's status, that is, part of a study or reporting for routine care, although basic clinical information was provided, including diagnosis and reason for study as per radiology requesting guidelines.
Statistical analysis
Statistical analysis aims to estimate the hazard rate associated with a group of 21 predictive factors as shown in Table 1 . Univariate analysis using the competing risk regression model was performed for all the proposed risk factors. Covariates that achieved a significance level of p0.2 were taken to the multivariate model. The multivariate model was built using the backward method. Variables were removed one by one till both model and individual factors achieved highest statistical significance.
Competing risk analysis was performed. Cumulative incidence function was used in estimating the probability of failure. The hazard associated with the proposed predictive risk factors was modeled using the sub-distribution hazard model proposed by Fine and Gray. 21 The study included two predictive models, developed using 95% confidence interval; first, modeled the hazard associated with the predictive risk factor on disease-specific events after HDC ASCT (event a HL IPS score 0-2 vs higher was included in the next step due to P-value.
Pre-transplant FDG-PET-based survival model in Hodgkin's lymphoma S Akhtar et al was defined as persistent disease, disease progression or recurrence); and second, modeled the associated risk on the disease-specific death (dying of disease) after HDC ASCT. The two proposed models studied the same group of predictive risk factors. The time frame used in modeling the disease-specific event or death was defined as time since transplant up to the occurrence of event or death, respectively, or last follow-up. Treatment-related mortality and death in remission because of other causes were considered as competing events. For response duration or disease-free interval, we initially analyzed refractory (no CR, only PR or relapsing within 3 months of CR after initial chemotherapy) vs relapsing between 3 and 12 months (P ¼ 0.92), hazard ratio (HR): 0.96 (0.47-1.9) and refractory vs relapsing after 12 months (P ¼ 0.1), HR: 0.55 (0.27-1.1). As there was no significant difference in refractory and relapsing between 3 and 12 months, they were merged as one group, as CR duration less than 12 months and compared against CR duration more than 12 months. Table 1 illustrates the results obtained by univariate and multivariate analysis using Fine and Gray Model.
Probability of disease-specific event and disease-specific death for patients with different risk factors was also calculated for the model. Statistical analysis was performed using R-2.14.1, available as a free software environment for statistical computing and graphics (http:// www.r-project.org). 22 Prognostic factor evaluation Prognostic factor data were collected both at the time of diagnosis and before the initiation of salvage chemotherapy as described in statistical section and shown in Table 2 and their significance in Table 1 .
RESULTS

Patients characteristics
From 1996 to 2011, 257 patients with HL underwent HDC ASCT. Time frame for various FDG-PET studies is shown in Figure 1 . One hundred and forty-one patients who had FDG-PET scans after salvage chemotherapy are reported here. At initial presentation, before the initiation of first line chemotherapy, these 141 patients had stages III and IV in 68%, BM positivity in 12%, extranodal involvement in 43%, spleen involvement in 35%, bulky disease in 38%, mediastinal involvement in 72% and B symptoms in 60% patients. Primary chemotherapy was adriamycin, bleomycin, vinblastin and dacarbazine (ABVD) in 129 (91.5%) patients. Remaining 12 patients, 5 had ABVD as second line, 3 had ABVD/ ABV alternating with CY/mechlorethamine-based therapy. Patients' characteristics before the initiation of salvage chemotherapy are shown in Table 2 that are evaluated for prognostic significance in all the statistics.
Out of 141 patients, 116 (82%) patients had FDG-PET before the initiation of salvage chemotherapy as a baseline to compare the FDG-PET with post salvage FDG-PET. Out of 141 patients, 130 (92%) patients also had post auto-SCT FDG-PET available. Median age was 25.5 (15-60) years at the time of HDC ASCT; 30 patients (21%) were between 14 and p21 years old. Tissue confirmation at relapse or progression was obtained in 91 (65%) patients. This was 84% for relapsed patient as compared with 50% for refractory patients (P ¼ 0.00003). In all, 50 patients had no tissue confirmation before salvage chemotherapy; 40 had refractory disease, 34 (68%) had stage III or IV disease, extranodal involvement in 27 (54%), spleen involvement in 15 (30%). Only 2out of 50 of these patient had CR duration of 412 months. All these patients with no biopsy confirmation had unequivocal clinical/radiological evidence of relapse or progression. Salvage chemotherapy, HDC and stem cell mobilization ESHAP (etoposide, solumedrol, cisplatinum and Ara-C) was primarily used as salvage chemotherapy in 133 (94%) patients and also for mobilization regimen for stem cell collection in 108 (77%) as we have reported previously. 23, 24 BEAM was used as HDC.
Salvage chemotherapy response evaluation and post HDC ASCT evaluation Patients on primary chemotherapy had clinical and radiological response evaluation in the middle and at the end of planned initial treatment. After starting salvage chemotherapy, all patients had response evaluation by FDG-PET and CT scan after two or three cycles of ESHAP or salvage chemotherapy. Primarily, only patients with responsive disease had stem cell mobilization and subsequent HDC ASCT. Exception was observed in few patients; 10 patients with CT scan responseoPR but on FDG-PET they had CR (4 patients) or PR (4 patients) and stable disease (2 patients); 4 patients with FDG-PEToPR had PR on CT scan (2 patients) or stable disease (2 patients) and 2 patients with PD on FDG-PET had CT scan PR. Patients with PD were not HDC ASCT candidate. The analysis represents patients who actually received HDC ASCT. Patients had restaging imaging evaluation after HDC ASCT at approximately 100 days to check the disease status and also when clinically required as shown in Table 3 . Median follow-up of all alive patients from auto-SCT is 33 months (12-81 months). At the time of current evaluation (Table 3) , 98 patients (69%) are still in CR. Median disease-specific EFS and OS have not reached for the entire group.
FDG-PET negative after salvage chemotherapy and outcome after HDC ASCT Sixty-five patients were FDG-PET negative after salvage chemotherapy. Of these 65 patients, 23 (35%) had negative CT scans and 42 (65%) had positive CT scans. After HDC ASCT, 10 FDG-PET negative patients (15%) had a disease-specific event.
FDG-PET positive after salvage chemotherapy and outcome after HDC ASCT Seventy-six patients were FDG-PET positive after salvage chemotherapy. Of these, 70 (92%) also had positive CT scans. After HDC ASCT, 37 FDG-PET-positive patients (49%) patients had a disease-specific event. Disease-specific event for FDG-PET positive vs negative is significant (Pearson w Prognostic model development and outcome For disease-specific event and death, 10 and 8 factors, respectively, had univariate P-value o0.2, and hence, included in to the multivariate analysis using Fine and Gray regression analysis (Table 1) .
Disease-specific event This model reached highest significance (P ¼ o0.00001) with three factors: positive FDG-PET scan (P ¼ 0.001), B symptoms (P ¼ 0.027) and mediastinal involvement at relapse (P ¼ 0.024). This model identified four groups with 0, 1, 2 and 3 risk factor (21:52:52:16) patients, respectively. Probability of disease-specific event at 5 years for 0, 1, 2 and 3 factors are 8%, 31%, 50% and 75%, respectively (P ¼ 0.0000006), as shown in Figure 2 . CR duration o12 months vs 412 months was the last factor removed from the model.
Disease-specific death
This model reached highest significance (P ¼ 0.0001) with two factors: positive FDG-PET scan (P ¼ 0.011) and HL-IPS of X3 at relapse (P ¼ 0.001). This model identified three groups with 0, 1 and 2 risk factor (27:58:56) patients, respectively. Probability of disease-specific event at 5 years for 0,1 and 2 factors are 7%, 29%, 52%, respectively (P ¼ 0.00003), as shown in Figure 2 . Mediastinal involvement was the last factor removed from the model. This score-based analysis indicates increasing risk of treatment failure for higher scores.
DISCUSSION
King Faisal Specialist Hospital and Research Center is a major transplant center, performing more than 250 transplants every year. There are emerging data indicating that patients with positive FDG-PET results after salvage chemotherapy or before HDC ASCT have poor outcome as compared with patients with negative FDG-PET. We identified positive FDG-PET scan, the presence of B symptoms and mediastinal involvement at relapse or progression with higher risk of disease-specific event. For disease-specific death, positive FDG-PET scan and HL-IPS of X3 at relapse or progression carry higher risk of death. Our model showed the significance of score-based model both for diseasespecific event (scores 0, 1, 2, 3, P ¼ 0.0000006) and disease-specific death OS (scores 0, 1, 2, P ¼ 0.00003).
Our study is addressing the importance of FDG-PET after salvage chemotherapy/pre-HDC ASCT along with other factors in predicting the outcome of relapsed or refractory HL. We have higher number of younger patients with HL as patients 14 years or older are seen and managed by adult oncologists. Also, patients with relapsed or refractory disease at other institutions are referred here for HDC ASCT, resulting in almost 50% of HDC ASCT for refractory disease. Like other studies, we identified FDG-PET, mediastinal involvement, HL-IPS and B symptoms as risk factors. Three patients died of treatment-related mortality while in CR (one due to treatment related myelodysplastic syndrome/leukemia), two patients died in remission due to unrelated causes and one had relapsed and died in car accident.
Pre-transplant FDG-PET-based survival model in Hodgkin's lymphoma S Akhtar et al
We had evaluated a large number of clinically relevant and important variables to construct a predictive model. Our report includes a uniformly treated group of patients. Studies reporting 20 or more HL patients in HDC ASCT setting are limited. [7] [8] [9] [10] [11] [12] [13] [14] [15] 25, 26 Many studies have combined various non Hodgkin's lymphoma (NHL) and HL together. Most studies analyzed FDG-PET as an individual risk factor rather than integrating it with all other factors. Most commonly reported adverse factors are short duration of CR, extranodal disease, mediastinal mass, poor response to salvage chemotherapy, the presence of B symptoms, stage III and IV at relapse, anemia and primary induction failure.
Before developing a score-based prognostic or predictive model, we reviewed the three commonly referred score-based prognostic or predictive models (all without a FDG-PET-based response evaluation) for patients with relapsed and refractory HL. Moskowitz et al. 27 reported 65 patients who had HDC ASCT and identified presence of B symptoms, extranodal disease and CR duration of less than 1 year as negative factors. Only 48% had ABVD. After ifosfamide, carboplatin and etoposide, patient received various radiation therapy protocols, not commonly used any more. Patients with 2 (15 patients) and 3 (10 patients) risk factors are limited. Fom 4754 patients registered in different German Hodgkin's Lymphoma Study Group, Josting et al. 28 identified 422 patients who relapsed. He reported stages III and IV, anemia and CR duration of less than 1 year as negative factors. These patients were treated very differently and only 140 had HDC ASCT. Risk factors were identified for the whole 422 group and then applied on various sub-groups rather than identifying specific risk factors for each group. Bierman et al. 29 evaluated all seven factors identified in the International Prognostic Factors Project on Advanced Hodgkin's Disease 20 on 379 patients who underwent HDC ASCT in his institution from 1984 to 1999. He reported low serum albumin, anemia, age 445 years and lymphopenia as negative factor. Almost 22% of these patients had HDC ASCT for second or 4second relapse, which is not a common scenario anymore. We had evaluated all these factors in our analysis. There are only two recent studies with 4100 patients who had FDG-PET before transplant, 15, 25 but treatment offered in these studies are purely institutional research based; augmented chemotherapy with or without radiation and tandem transplant. Schot et al. 8 reported 101 patients (78 various NHL and 23 HL), 77 of whom underwent HDC ASCT. They integrated FDG-PET response with second age-adjusted international prognostic score and relapsed Hodgkin's prognostic score. 28 The patients with two or three risk factors and a positive pre-transplant FDG-PET had dismal prognosis same as shown in our study. Our report supports previous studies reporting a negative impact of FDG-PET positivity before HDC ASCT both on diseasespecific event and mortality. Prospective studies with an appropriate sample size to validate this model should be the next step.
It should be clear that at this time, the standard treatment for all these patients remains HDC ASCT. Our model, after validation, can be used for selecting potentially high-risk patients and offering them clinical studies and other treatments before, during or after standard HDC ASCT.
